Montreal (QC, Canada) Sept 8th, 2026 – Telescope Therapeutics, a discovery-stage biotechnology company developing targeted therapies to reshape the fibrotic response and prevent organ failure, today announced the appointment of Myriam Lavoie, as Chief Executive Officer.
Co-founded by leading clinicians and translational researchers in partnership with Montreal-based life science venture studio Vitruvius, Telescope Therapeutics is built to overcome the translational hurdles long associated with chronic fibrotic diseases. Mrs. Lavoie joins the company to guide corporate strategy, advance operational momentum, and drive the lead program forward.
"On behalf of the founding team, we are thrilled to welcome Myriam to Telescope Therapeutics. Her leadership will be invaluable as we advance our work in cardiac fibrosis and expand our reach into broader fibrotic diseases.’’ shared Dr. Renzo MD, Co-founder of Telescope Therapeutics and CEO of Vitruvius Venture Studio.
Telescope focuses ond eveloping novel therapeutic candidates selectively reshaping the fibrotic response, halting the progression toward organ failure while preserving critical tissue repair mechanisms. To drive this drug discovery pipeline, the company leverages a human-relevant preclinical platform pairing patient-derived induced pluripotent stem cell disease models with real-time biosensors. By profiling disease biology directly in human systems early in development, Telescope identifies and advances high-conviction therapeutic candidates with superior clinical translatability.
‘’Learning about the sheer scale of this unmet need and how legacy discovery models have held back real progress made it impossible not to care deeply about this mission. I couldn't be more excited to officially join Telescope Therapeutics as CEO! Stepping into chronic fibrotic diseases has been an eye-opening journey. What made this step an absolute yes is the extraordinary community behind it. I am honored to partner with our co-founders, Drs. Terry Hebert, Renzo Cecere, MD, and Nadia Giannetti, MD alongside our brilliant team of scientists and key academic collaborators who are working together to bring our vision to life.’’ said Myriam Lavoie, CEO at Telescope Therapeutics.
About Telescope Therapeutics
Telescope Therapeutics is advancing a targeted pipeline to halt and reverse fibrotic diseases. Powered by its unique disease modeling platform, Telescope combines induced pluripotent stem cell-based models with advanced biosensors capturing human-relevant disease biology early in drug discovery. With this predictive platform, Telescope's goal is to bring effective therapeutic solutions to patients affected by fibrotic diseases.
For more information, visit www.telescopetherapeutics.com
Media Contacts: Myriam Lavoie, MS, Telescope Therapeutics (CEO) myriam.l@telescopetherapeutics.com
